AS	Active surveillance
AUA	American Urological Association
AUC	Area under the curve
BMI	Body mass index
CaPSURE	Cancer of the Prostate Strategic Urologic Research Endeavour
CAPRA	Cancer of the Prostate Risk Assessment
CCP	Cell Cycle Progression score
CI	Confidence interval
CPG	Cambridge Prognostic Group
DNA	Deoxyribonucleic acid
EAU	European Association of Urology
EPI	ExoDx Prostate Intelliscore
EV	Extracellular vesicle
FOI	Freedom of information
GAP3	Global Action Plan 3 (Movember Foundation consortium)
GG	Gleason Grade group
GPS	Genomic Prostate Score
GS	Gleason Score
hK2	Human kallikrein-related peptidase 2
HR	Hazard ratio
IQR	Interquartile range
ISUP	International Society of Urological Pathology
MIC1	Macrophage inhibitory cytokine-1
mpMRI	Multiparametric magnetic resonance imaging
MSMB	Microseminoprotein beta
NCCN	National Comprehensive Cancer Network
NICE	National Institute for Health and Care Excellence
NPCA	National Prostate Cancer Audit
NPV	Negative predictive value
OR	Odds ratio
PASS	Prostate Active Surveillance Study
PCA3	Prostate Cancer Antigen 3
PCUK	Prostate Cancer UK
PHI	Prostate Health Index
PI-RADS	Prostate Imaging Reporting and Data System
PRIAS	Prostate Cancer Research International Active Surveillance study
PSA	Prostate-specific antigen
PUR	Prostate Urine Risk
RCT	Randomised controlled trial
RNA	Ribonucleic acid
SD	Standard deviation
SEER	Surveillance, Epidemiology and End Results
STHLM3	Stockholm3
STRATCANS	Stratified Cancer Surveillance
T-stage	Tumour stage